EQT Life Sciences Co-Leads a Significant Funding Round
EQT Life Sciences has made a remarkable move by leading a USD 56 million Series D financing round for Neuros Medical, Inc., a pioneering U.S. medical device company. This funding aims to pave the way for the U.S. commercialization of Altius, an FDA-approved direct electrical nerve stimulation system. This device is crafted specifically for addressing chronic and intractable post-amputation pain that many amputees endure on a daily basis.
The Impact of Post-Amputation Pain
Post-amputation pain is a critical issue, affecting around 80% of amputees. Unfortunately, the current treatment options for this condition are quite limited, with few effective non-opioid solutions available in the market. This gap in efficient treatment alternatives underscores the importance of advancements like Altius, which not only targets the source of pain but also offers a beacon of hope for those suffering.
Altius: A Game-Changer in Pain Management
The Altius system is a breakthrough technology that delivers targeted nerve stimulation. This on-demand therapy is designed to significantly alleviate the pain experienced by adult amputees. What makes Altius unique is that it is currently the only FDA-approved device specifically aimed at managing post-amputation pain, setting it apart in a crowded market.
Voices from Industry Leaders
David Veino, President and CEO of Neuros Medical, expressed his enthusiasm regarding the funding, stating that it allows the company to expand its operations and make this critical treatment more accessible to those in need. The support they have received from EQT and their partners plays a significant role in their mission to alleviate pain and improve quality of life for amputees.
Additionally, Fouad Azzam, Ph.D., a partner in EQT's Life Sciences advisory team, emphasized the urgency of addressing chronic pain management. He highlighted that Neuros Medical stands at the forefront of tackling this vital issue and that through this partnership, they hope to enhance the lives of amputees everywhere.
Utilizing the Funding for Commercial Expansion
The proceeds from this financing round will be critical for Neuros Medical as they initiate and support the commercialization of Altius across the U.S. market. By providing necessary resources, the company aims to ensure that this innovative pain management solution reaches those who need it most, effectively transforming patient care in this often overlooked area of health.
Looking Ahead
The collaboration between EQT and Neuros Medical marks a significant step not just for the companies involved, but for the healthcare landscape concerning pain management. With ongoing advancements and increased focus on this area, the future looks promising for those living with post-amputation pain.
Frequently Asked Questions
What is the purpose of the USD 56 million funding?
The funding is aimed at supporting the commercialization of Altius, a device intended to alleviate chronic post-amputation pain.
Who is behind the company Neuros Medical?
Neuros Medical, Inc. is a U.S.-based medical device company focusing on innovative treatments for pain management, particularly after amputations.
What is Altius?
Altius is an FDA-approved direct electrical nerve stimulation system designed to treat chronic post-amputation pain in adult amputees.
How prevalent is post-amputation pain?
Post-amputation pain affects up to 80% of amputees, representing a significant unmet medical need.
What does this funding mean for the future of pain management?
The funding represents hope for expanded access to effective non-opioid pain management options for amputees and reflects a growing commitment to address chronic pain.
